About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

379188 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 07/24/2021.
This website is for US healthcare professionals
close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Our Science

lisocabtagene maraleucel (liso-cel; JCAR017; Anti-CD19 CAR T Cells)

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Proposed Mechanism of Action

Liso-cel is an investigational chimeric antigen receptor (CAR) T cell therapy designed to target CD19,1,2?which is a surface glycoprotein expressed during normal B-cell development and maintained following malignant transformation of B cells.3-5?Liso-cel CAR T cells aim to target and CD-19 expressing cells through a CAR construct that includes an anti-CD19 single-chain variable fragment (scFv) targeting domain for antigen specificity, a transmembrane domain, a 4-1BB costimulatory domain hypothesized to increase T-cell proliferation and persistence, and a CD3-zeta T-cell activation domain.1,2,6-9 The controlled manufacturing process for liso-cel results in a defined composition therapy consisting of CD8+ and CD4+ CAR T cells; however, the clinical significance of defined composition is unknown.1,10

Liso-cel Proposed Mechanism of Action